Ahold Delhaize Pays $40 Million to Settle Inflated Prescription Price Reporting Allegations

Ahold Delhaize Pays $40 Million to Settle Inflated Prescription Price Reporting Allegations

Ahold Delhaize USA, the parent company of supermarket chains including Giant, Hannaford, Stop & Shop, and Food Lion, has agreed to pay $40 million to resolve U.S. Department of Justice allegations that it submitted inflated prescription drug pricing data to federal health care programmes, overcharging Medicare Part D, Medicaid, and Tricare.

What the Case Is About

The settlement does not concern what consumers paid at the pharmacy counter. Federal authorities alleged that Ahold Delhaize failed to report discounted prescription prices as its “usual and customary” rates when billing government health programmes — causing those programmes to reimburse pharmacies at artificially elevated amounts.

Under federal rules, pharmacies are required to report their standard going rate for a drug, which should reflect discounts offered to enrolled savings programme members. By reporting higher figures instead, the government contends, the company extracted inflated reimbursements from taxpayer-funded programmes.

How the Case Came to Light

The allegations were first raised by Lawrence LaBenne, a pharmacist who worked at an Ahold Delhaize supermarket location in Pennsylvania. Under the civil settlement agreement, LaBenne will receive more than $6 million as a whistleblower award.

Whistleblower provisions under the False Claims Act allow private individuals to file suits on behalf of the government and collect a share of any recovery — a mechanism that has increasingly driven pharmacy billing enforcement actions.

Settlement Breakdown

Of the $40 million total, approximately $32.9 million will go to the federal government, with the remainder distributed among participating states. Ahold Delhaize stated the settlement resolves allegations only and does not constitute an admission of wrongdoing.

Regulatory Stakes

Assistant Attorney General Brett Shumate of the DOJ’s Civil Division said federal health care programmes depend on accurate pricing disclosures to calculate reimbursements correctly. “When pharmacies report inflated ‘usual and customary’ prices, federal health care programs ultimately pay more than they should,” he said.

Scott J. Lampert, acting deputy inspector general at the U.S. Department of Health and Human Services Office of Inspector General, added that inaccurate pricing practices risk undermining the integrity of taxpayer-funded health care programmes.

Wider Industry Context

The case reflects a sustained regulatory focus on pharmacy billing practices across the United States. Ahold Delhaize is not alone: CVS Health has faced federal and state False Claims Act litigation over pharmacy reimbursement and billing compliance, and several other major retailers have confronted similar investigations.

The settlement also arrives at a financially pressured moment for Ahold Delhaize. In its first-quarter fiscal 2026 earnings, the company disclosed that U.S. pharmacy sales were being hit by pricing changes tied to the Inflation Reduction Act — a headwind it now expects to reduce U.S. pharmacy revenues by approximately $450 million.

Together, the regulatory settlement and the IRA-driven revenue compression signal a structural reckoning for pharmacy operations embedded within grocery retail — a model that has long used discounted drug pricing as a customer retention tool, but now faces tightening scrutiny on both the regulatory and legislative fronts.